We are a multi-disciplinary research group based at the School of Biological Sciences at the University of Edinburgh interested in engineering and manufacturing highly effective therapies using two of the most disruptive technologies of the last 20 years: AI and engineering biology.

Our group is currently focusing on developing new therapies for the treatment of a class of rare diseases known as Lysosomal Storage Disease (LSDs). We are primarily focusing on Fabry disease, with the aim of bringing to the clinic a treatment that is both effective and sustainable to use.